Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
4(57%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
14%
Ph phase_3
2
29%
Ph phase_1
4
57%

Phase Distribution

4

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(3)

Detailed Status

Completed3
Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (57.1%)
Phase 21 (14.3%)
Phase 32 (28.6%)

Trials by Status

completed343%
active_not_recruiting114%
recruiting343%

Recent Activity

4 active trials
Showing 5 of 7
recruitingphase_1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT05536141
recruitingphase_3

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719
recruitingphase_2

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

NCT07397611
active_not_recruitingphase_3

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

NCT07000149
completedphase_1

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

NCT06919991
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05536141Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Recruiting
NCT07011719Phase 3

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting
NCT07397611Phase 2

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Recruiting
NCT07000149Phase 3

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Active Not Recruiting
NCT06919991Phase 1

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Completed
NCT05999513Phase 1

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Completed
NCT05117554Phase 1

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7